RedHill Biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
Latest News
-
April 24th, 2012
RedHill Biopharma commenced advanced clinical trial with RHB-103 (migraine) -
April 18th, 2012
RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-102 (prevention of nausea and vomiting) -
March 5th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) featured by the Israeli Ministry of Foreign Affairs -
February 15th, 2012
RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began -
February 13th, 2012
RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (prevention of nausea and vomiting)
See More News